![]() |
市場調查報告書
商品編碼
1831901
2025 年至 2033 年重組 DNA 技術市場報告(按產品、組件、應用、最終用戶和地區)Recombinant DNA Technology Market Report by Product, Component, Application, End User, and Region 2025-2033 |
2024年,全球重組DNA技術市場規模達7,962億美元。展望未來, IMARC Group預計到2033年,該市場規模將達到1.1434兆美元,2025-2033年期間的複合年成長率(CAGR)為3.9%。基因工程和生物技術的持續進步、生物製藥需求的不斷成長、個人化醫療的日益普及以及慢性病盛行率的上升,是推動市場成長的主要因素。
生物製藥需求不斷成長
對單株抗體、疫苗和胰島素等生物製藥產品日益成長的需求是主要驅動力。例如,根據IMARC的數據,全球生物製藥市場規模在2023年達到3,005億美元。展望未來, IMARC Group預計到2032年,市場規模將達到6,439億美元,2024-2032年期間的複合年成長率(CAGR)為8.6%。重組DNA技術在這些產品的生產中至關重要,而這些產品對於治療各種慢性疾病至關重要。預計這些因素將在未來幾年推動重組DNA技術市場的發展。
慢性病盛行率不斷上升
癌症、糖尿病和心血管疾病等慢性疾病的日益普及是推動市場成長的重要因素之一。例如,根據IDF糖尿病地圖集(2021),20至79歲的成年人中10.5%患有糖尿病。此外,到2045年,每八人中就有一人(約7.83億人)將罹患糖尿病,增幅達46%。重組DNA技術能夠生產必需的治療性蛋白質和激素,例如用於糖尿病管理的胰島素和用於貧血治療的促紅血球生成素。這些因素正在進一步積極影響重組DNA技術產業市場。
技術進步
CRISPR 和其他基因編輯工具等持續的技術創新,正在提升重組 DNA 技術的精準度和應用範圍,進而推動市場擴張。例如,2024 年 8 月,一群德國研究人員開發了一種增強型 CRISPR(成簇規律間隔短回文重複序列)技術,以解決和改善針對血液腫瘤和實體瘤的 CAR-T 細胞療法中現有的障礙。 CRISPR 是一項獨特的技術,它使遺傳學家和醫學研究人員能夠透過移除、插入或改變 DNA 序列來編輯基因組的某些部分,從而提升重組 DNA 技術系統市場的收入。
The global recombinant DNA technology market size reached USD 796.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 1,143.4 Billion by 2033, exhibiting a growth rate (CAGR) of 3.9% during 2025-2033. The ongoing advancements in genetic engineering and biotechnology, the growing demand for biopharmaceuticals, increasing shift towards personalized medicines, and the rising prevalence of chronic diseases are primarily driving the market's growth.
Rising Demand for Biopharmaceuticals
The rising demand for biopharmaceuticals, including monoclonal antibodies, vaccines, and insulin, is a major driver. For instance, according to IMARC, the global biopharmaceutical market size reached US$ 300.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 643.9 Billion by 2032, exhibiting a growth rate (CAGR) of 8.6% during 2024-2032. Recombinant DNA technology is pivotal in the production of these products, which are essential for treating various chronic diseases. These factors are expected to propel the recombinant DNA technology market in the coming years.
Increasing Prevalence of Chronic Diseases
The increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular diseases, is one of the significant factors driving the market's growth. For instance, according to the IDF Diabetes Atlas (2021), 10.5% of adults aged 20 to 79 suffer from diabetes. Also, by 2045, one in every eight persons, or roughly 783 million, will have diabetes, representing a 46% rise. Recombinant DNA technology enables the production of essential therapeutic proteins and hormones, such as insulin for diabetes management and erythropoietin for anemia treatment. These factors are further positively influencing the recombinant DNA technology industry market.
Technological Advancements
Continuous technological innovations, such as CRISPR and other gene-editing tools, are enhancing the precision and application scope of recombinant DNA technology, driving the market expansion. For instance, in August 2024, a group of German researchers developed an enhanced CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technique to solve and improve existing obstacles in CAR-T cell therapy that targets both blood and solid tumors. CRISPR is a unique technology that enables geneticists and medical researchers to edit portions of the genome by removing, inserting, or changing DNA sequences, thereby boosting the recombinant DNA technology systems market revenue.
According to the recombinant DNA technology market outlook, recombinant DNA technology enables the development of gene therapies to treat genetic disorders like cystic fibrosis, hemophilia, and muscular dystrophy. This technology has revolutionized the production of human insulin, making it more accessible for diabetic patients. While crops like Bt cotton, Roundup Ready soybeans, and Golden Rice have been developed using rDNA technology to enhance resistance to pests, herbicides, and to improve nutritional content.
According to the recombinant DNA technology market overview, an expression system refers to the host organism and the molecular machinery used to produce recombinant proteins. It includes the host cells, the vectors, and the regulatory sequences necessary for gene expression. While a cloning vector is a DNA molecule used to carry foreign genetic material into a host cell, where it can be replicated and/or expressed. It is used in the development of genetically modified crops with desirable traits such as pest resistance and improved nutritional content.
Recombinant DNA technology is used to develop genetically modified (GM) crops with desirable traits such as increased yield, pest resistance, herbicide tolerance, and improved nutritional content. This is crucial for meeting the food demands of a growing global population. Apart from this, in health and disease, it enables the production of insulin, growth hormones, monoclonal antibodies, and vaccines. The demand for effective and affordable biopharmaceuticals drives this sector. Besides this, it is also used to engineer microorganisms that can break down pollutants and toxins in the environment. This helps in cleaning up oil spills, heavy metals, and other environmental contaminants.
In biotechnology and pharmaceutical companies, recombinant DNA technology is used to produce human insulin in bacteria, which is a major advancement over previous methods using animal insulin. Companies use rDNA to develop monoclonal antibodies for the treatment of various diseases, including cancer and autoimmune disorders. While government research institutes like the CDC use rDNA technology to monitor and study pathogens, enabling rapid response to outbreaks and epidemics.
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.
According to the recombinant DNA technology market statistics, North America is one of the prominent regions for rDNA technology due to significant investments in biotechnology and pharmaceuticals. Moreover, Europe has a well-established biotechnology sector, particularly in countries like Germany, France, and the UK. The growth of the European region is driven by the strong collaboration between academic institutions, research institutes, and industry.
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include: